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Dutch guidelines for pharmacoeconomic research.
DALYs were calculated using data on number of deaths
due to gastroenteritis and age at death from Statistics
Netherlands. Disability weights for both mild and severe
cases of gastroenteritis were taken from a Dutch national
study on the burden of diseases. RESULTS: Of the 4860
participants in the cohort, 1052 case episodes were
observed. Of these cases, 774 (74%) participated in the
case-control component. Of these, 646 (83%) completed
data collection. The overall standardised incidence of 
gastroenteritis was 283 per 1000 person-years, with an
estimated total of 4.5 million cases per year. Total costs
per case were €68.80, with productivity losses (€55.50)
being the major cost driver. Total cost to society were esti-
mated at €308 million in 1999 (95% CI €221–393
million). Gastroenteritis was associated with a loss of
67,000 DALYs. CONCLUSIONS: Although costs and
disease burden are low for individual cases, gastroenteri-
tis is associated with a high disease burden and con-
siderable costs to society due to a high incidence in the
population.
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OBJECTIVES: Intravenous Proton Pump Inhibitors
(PPIs) are widely used in hospital. The galenic formula-
tion of esomeprazole tablets (Multi Unit Pellet System)
enables water dispersion and subsequent administration
through a gastric tube (GT), thus offering an alternative
to injectable PPIs. The primary objective of this study was
to estimate the percentage of hospital patients treated
with intravenous PPIs that are potential candidates to a
treatment with esomeprazole tablets administered via a
GT. Secondary objectives were to derive the subsequent
savings in terms of drug acquisition cost and nurses time
saving. METHODS: Hospitals, stratiﬁed on their admin-
istrative status, were randomly selected. In each hospital,
departments consuming more than 80% of the total
injectable PPIs were identiﬁed. Patient data collection
(including presence of a GT) was done during one single
day. The time to administrate injectable PPI and
esomeprazole tablets through a GT was estimated by
nurses; drug cost calculations were done with undis-
counted prices including taxes. RESULTS: A database
including 179 patients in 19 different hospital centres was
collected. Mean age (SD) was 61.9 (16.3) years and
53.9% of patients were male. Patients were hospitalised
for 13.1 (16.5) days in surgery department (41%),
medical department (37.1%), intensive care unit (21.9%).
A total of 46.6% of patients were hospitalised for cancers
and 30.1% for digestive diseases. Total number of
patients which had GT was 33.3%. Median nurse times
to administrate injectable PPI and esomeprazole tablets
through a GT were respectively 5 and 3 minutes (-40%),
while the drug costs were respectively €8.08 and €1.49 
(-82%). CONCLUSIONS: This study shows that 33%
of patients treated with injectable PPI have a gastric tube.
These patients are potential candidates to be treated with
esomeprazole tablet through a gastric tube with signiﬁ-
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The PROGRESS trial demonstrated the effectiveness of
perindopril/indapamide in secondary stroke prevention
(SSP). No existing economic study has incorporated these
ﬁndings in a cost-beneﬁt analysis. OBJECTIVES: The
objective of this analysis was to evaluate the cost/beneﬁt
of perindopril/indapamide in SSP. METHODS: The
model used a decision tree approach to estimate direct
cost savings associated with SSP for a hypothetical cohort
of 10,000 ﬁrst stroke survivors from an HMO’s perspec-
tive (1 Mio covered lives) over a 3-year time period. Inci-
dence estimates for 2nd stroke and Health care utilization
as well as pharmacoeconomic estimates are presented 
for each year and separated for the two major stroke
types (ischaemic and hemorrhagic stroke). First, stroke
incidence and transition probabilities for Health care 
utilization were ed from the published epidemiologic 
literature, incidence of second strokes from the
PROGRESS trial. Cost for stroke-related hospitalization
and re-hospitalization, rehabilitation, nursing home, and
ambulatory care derived from national data and pub-
lished literature. Historical cost data was inﬂation-
adjusted to 2001 values, savings in the 2nd and 3rd year
were discounted at 3%, and health care CPI inﬂation-
adjusted at 4.7%. Treatment and control group (no SSP
medication) were replenished after the 1st and 2nd year
in equal numbers with newly SSP eligible patients (new
ﬁrst stroke survivors of the HMO population). Drug
prices were deﬁned as WAC-20% plus $5 co-pay. Sensi-
tivity analysis on stroke incidences, selected transition
probabilities and costs will be presented. RESULTS: SSP
with perindopril/indapamide saved 28 lives and 110
strokes in the ﬁrst year (after 3 years 169 and 325 respec-
tively). Treatment achieved a net beneﬁt of $803,000 in
the ﬁrst, $3,267,253 in the second and $6,207,814 by the
third year. The cost per stroke prevented was $24,648 and
$47,412 per death averted over the 3 year period. 
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CONCLUSIONS: SSP with perindopril/indapamid saves
lives and Health care costs.
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OBJECTIVES: Accurate information about resources use
and costs of stroke is necessary for informed health plan-
ning activities. The aim of this study was to determine the
patterns of health resources use among stroke patients
and to estimate the total costs (direct medical and non
medical and indirect production losses) of stroke in Spain
for 2001. METHODS: The cost-of-illness method was
used. Direct and indirect costs were estimated using
prevalence costs. Indirect costs (productivity costs) were
estimated using the approach of human capital theory
from lost earning attributable to stroke related mortality
and morbidity. Data on resource use were retrospectively
collected from hospitals and questionnaires. The costs of
stroke during the ﬁrst, second and third year after stroke
and the total costs of stroke were estimated. RESULTS:
We gathered information from 350 patients. The average
cost per stroke survivor during the ﬁrst, second and third
year, in Spain during 2001, were estimated to be €10,189,
€7,662, and €5,614 respectively. The most important 
categories of cost during the ﬁrst year were acute hospi-
talisation and rehabilitation. During the second and third
year the most important categories of costs were drugs,
rehabilitation and tests. Stroke cost €1402.34 million to
the Spanish health care system, representing 4% of the
total public health care expenditure, €3197.55 million in
informal care and €392.95 million for productivity loss.
The total annual cost of all stroke related burden was
€4992.84 million. CONCLUSIONS: Stroke is a leading
public health problem in Spain in term of the economic
burden of disease. Given the magnitude of these costs,
investigation of the cost-effectiveness of different inter-
ventions for stroke should become a priority.
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OBJECTIVES: The risk of VTE after hip fracture surgery
has been clearly demonstrated by randomized clinical
trials designed for the registration of a new anti-
thrombotic agent. Nevertheless as the diagnosis of VTE
was based on a systematic venography which is not rou-
tinely performed in current practice, real life data based
on the occurence of clinical events are needed from both
an epidemiological and economic point of view.
METHODS: The VEEP (VEnous Embolism in hiP frac-
ture) cohort study was a prospective cohort study run in
two sizeable French public hospitals. During a 1-year
period, patients hospitalized for hip fracture were con-
secutively included and followed up for three months.
Resource use data concerning type of surgery, anti-throm-
botic treatments (preventive, curative) and clinical events
(Deep Vein Thrombosis, Pulmonary Embolism, bleed-
ings) were collected. RESULTS: One hundred sixty-nine
patients were included in the cohort study (mean age 84.6
years, 82% female). History of previous VTE was found
in 15% of the patients. Mean length of stay in acute care
was 16.1 days (+/-11). Mean length of stay in rehabili-
tation unit was 41.6 days (+/-22.7). A total of 162
patients received an antithrombotic treatment post-oper-
atively (in most of cases a low molecular weight heparin).
The cumulative rate of VTE clinically suspected and con-
ﬁrmed by echo-doppler was higher than expected (13.6%
at 3 months) and 80% of the VTE events occur after dis-
charge from acute care. Only one pulmonary embolism
was reported. Length of stay was signiﬁcantly higher in
patients having experienced a VTE (nine additional days
on an average) leading to substantial additional costs.
CONCLUSION: Despite standard antithrombotic pro-
phylaxis the risk of clinical VTE is high after hip fracture
surgery and even higher after the acute phase, highlight-
ing the need for more effective preventive therapies.
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OBJECTIVE: To project the life expectancy (LE) and
costs of treating patients with diabetes, hypertension, and
microalbuminuria with irbesartan 300mg. METHODS:
A long-term Markov model simulated progression from
microalbuminuria to nephropathy, doubling of serum 
creatinine, end-stage renal disease (ESRD), and all-cause
